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doi:10.101Busulfan and Cyclophosphamide (Bu/Cy) as
a Preparative Regimen for Autologous Stem Cell
Transplantation in Patients with Non-Hodgkin
Lymphoma: A Single-Institution Experience
Matthew Ulrickson,1 Julie Aldridge,2 Haesook T. Kim,2 Ephraim P. Hochberg,1
Peter Hammerman,1 Christine Dube,1 Eyal Attar,1 Karen K. Ballen,1 Bimalangshu R. Dey,1
Steven L. McAfee,1 Thomas R. Spitzer,1 Yi-Bin Chen1High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been established as a stan-
dard form of therapy for patients with non-Hodgkin lymphoma (NHL). While many high-dose chemotherapy
combinations are used, no single regimen has proved superior over another. Here, we report our single cen-
ter’s experience in patients with NHL undergoing ASCTwith the combination of busulfan and cyclophospha-
mide (Bu/Cy). This study is a retrospective analysis of 78 consecutive patients with NHL who underwent
ASCT with Bu/Cy at Massachusetts General Hospital Cancer Center. Data were collected through review
of electronic medical records. A total of 78 patients with NHL underwent ASCTwith Bu/Cy preparative ther-
apy between 1996 and 2006. Median follow-up for survivors was 5.0 years (range, 6 months to 12 years).
Significant transplantation-associated complications included 9 documented bacterial infections, 4 cases of
engraftment syndrome, 3 cases of hepatic veno-occlusive disease (VOD), 6 cases of cardiac complications,
and 2 cases of pulmonary fibrosis. The 100-day treatment-related mortality (TRM) was 1%. At 3 years, pro-
gression-free survival (PFS) was 48% (95% confidence interval [CI]5 37% to 59%) and overall survival (OS)
was 65% (95% CI5 53% to 74%). Our data indicate that in patients with NHL undergoing ASCT, Bu/Cy has
efficacy and toxicity comparable to that of other reported regimens.
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Approximately 54,000 new cases of non-Hodgkin
lymphoma (NHL) are diagnosed each year in the
United States [1]. Individuals who have aggressive
disease that proves refractory to initial therapy or
who experience relapse after an initial remission are
known to have a poor prognosis with standard chemo-
therapy alone. In 1995, the Parma group established
the significant benefit of high-dose chemotherapy fol-1Department of Hematology/Oncology, Massachusetts
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6/j.bbmt.2009.07.014lowed by autologous stem cell transplantation (ASCT)
in patients with chemosensitive relapsed/refractory
aggressive NHL [2]. Evidence has also been shown
for the benefit of ASCT in indolent histologies of
NHL, although its role is less well defined [3,4].
There are many high-dose combination prepara-
tive regimens for ASCT, with the choice usually based
on each center’s own institutional experience. Several
centers have published their single-center results
with such regimens as carmustine or total body irradi-
ation (TBI) combined with etoposide (E) and cyclo-
phosphamide (Cy), TBI with E and Cy, carmustine/
cytarabine/Cy/E, Cy-carmustine-etoposide, and car-
mustine-E-cytarabine-melphalan (Mel); no single reg-
imen has ever been shown to be clearly superior over
another, however [5-7]. For many years, busulfan
(Bu) has been used in combination, usually with Cy
and with or without etoposide, in preparation for mye-
loablative (MA) ASCT. Over the last decade, use of an
i.v. preparation of Bu has improved the accuracy of Bu
dosing, with resulting improvement in regimen-re-
lated toxicity, presumably through minimization of1447
1448 Biol Blood Marrow Transplant 15:1447-1454, 2009M. Ulrickson et al.interpatient variations in oral absorption. While Bu/
Cy/E has been described as a preparative regimen for
ASCT in NHL [8], a large series using the combina-
tion of Bu/Cy alone has not yet been published.
Here we describe our institution’s experience with
Bu/Cy to present an additional option for high-dose
chemotherapy with ASCT in patients with NHL.METHODS
A total of 78 patients with relapsed/refractoryNHL
betweenMarch 1996 andMay 2006 received BuCy, fol-
lowed by ASCT, at Massachusetts General Hospital
(MGH)CancerCenter.The hospital’s Institutional Re-
view Board approved the study design. A retrospective
review of electronic medical records was performed to
assess the safety and efficacy of this conditioning regi-
men.All patientsmet institutional standardASCTcrite-
ria, including an Eastern Cooperative Oncology Group
performance status of 0 or 1, total bilirubin\2.0 mg/
dL, creatinine\2.0 mg/dL, a diffusion coefficient of
carbon monoxide (DLCO) of. 50% of the predicted
value corrected for hemoglobin, and a left ventricular
ejection fraction. 45%.Histological subtypeswere de-
termined according to the currentWorld Health Orga-
nization (WHO) formulation. Disease was staged
according to the Ann Arbor staging system. The status
of disease at the timeofASCTwas defined as first or sec-
ond remission (either partial [PR] or complete [CR]).
CRwas defined as complete disappearance of all clinical
and radiographic evidence of disease and disappearance
of all disease-related symptoms, consistent with the def-
inition of the InternationalWorkingGroup. PRwas de-
fined as a$ 50% decrease in the sum of the products of
the greatest diameter in the 6 largest nodes or nodules
without the appearance of new disease sites [9]. In the
absence of clear data indicating that a patient was in
CR, PR status was assumed.
Beginning on day 7 pre-ASCT, each patient
received either 1 mg/kg oral Bu or, after December
2000, 0.8 mg/kg i.v. Bu every 6 hours for 4 days, for a to-
tal of 14 or 16 doses, followed by i.v. Cy 60 mg/kg daily
for 2 days on days 3 and 2 pre-ASCT. Patients over age
50 years received 14 doses, while those under age 50
years received 16 doses. Oral Bu was dosed halfway be-
tween ideal and actual body weight for patients
weighing. 20% above their ideal body weight. i.v. Bu
dosing was based on either actual or ideal body weight,
whichever was lower. Pharmacokinetic data for Bu dos-
ing were not obtained. Cy was dosed at 50% between
ideal and actual body weight for patients
weighing. 20% above their ideal body weight. On
day 0 (ie, day of ASCT), patients received an infusion
of previously collected autologous peripheral blood
stem cells (PBSCs; with and without bone marrow
[BM] supplementation) at a minimum dose of 2 106CD341 cells/kg. One patient received 1.3 106 cells/
kg due to an inability to collect the desired number of
stem cells. After stem cell infusion, the patients were
maintained in the hospital until neutrophil
engraftment, as defined by an absolute neutrophil count
(ANC). 500/UL on 2 consecutive days. Platelet en-
graftment was defined by an unsupported platelet
count. 50,000/UL on 2 consecutive occasions. Pa-
tients were maintained on antimicrobial prophylaxis in-
cluding fluconazole and fluoroquinolone, whereas
neutropenic, trimethoprim-sulfamethoxazole (TMP/
SMX) fromday -7 throughday -1 and then after engraft-
ment through day1100, and acyclovir up to 1 year post-
transplantation. Supportive care also included i.v.
filgrastim (granulocyte colony-stimulating factor [G-
CSF]) 5 mg/kg daily after transplantation until the total
white blood cell count was. 5000/UL, ursodiol for
prevention of hepatic veno-occlusive disease (VOD),
mesna for prevention of hemorrhagic cystitis, and phe-
nytoin during Bu therapy [10]. Patients received irradi-
ated and leukocyte-reduced red blood cell and platelet
transfusions in accordance with institutional standards.
Patients were discharged from the hospital when en-
graftment had been achieved and they were free of any
evidence of infection and clinically stable. Follow-up
was limited to thedata available in the electronicmedical
record system of MGH, which includes both inpatient
and outpatient records. Some of the patients in this se-
ries have been included in previous reports [11,12].Statistical Methods
Patient baseline characteristics were described
descriptively. Overall survival (OS) and progression-
free survival (PFS) were calculated using the Kaplan-
Meier method. Prognostic factors for OS and PFS
were examined using a proportional hazards model.
PFS was defined as the time from day 0 to the first of
relapse, progression of disease (either radiographically
or pathologically), or death from any cause. Patients
who were alive without relapse or progression were
censored at the time last seen alive when relapse/prog-
ression-free. OS was defined as the time from day 0 to
death from any cause. Patients who were alive or lost to
follow-up were censored at the time last seen alive.
Prognostic factors for OS and PFS were examined
using Cox proportional hazard models.RESULTS
Patient Characteristics
Clinical characteristics of the 78 patients with
NHL who underwent ASCT using Bu/Cy are given
in Table 1. All patients during this period with NHL
who underwent ASCT at MGH were treated with
BuCy, with the exception of 6 patients enrolled on
Table 1. Baseline Patient Characteristics (n5 78)
n (%)
Number 78 (100)
Age, years, median (range) 57 (24, 78)
Male sex 42 (54)
Diagnosis
DLBCL 37 (48)
Follicular 18 (24)
Mixed 4 (5)
HIV NHL 6 (8)
Other 12 (15)
Previous courses of chemotherapy, median (range) 2 (1, 4)
Cell source
Peripheral blood stem cells 75 (96)
Bone marrow 1 (1)
Both 2 (3)
Status at ASCT*
CR1 2 (3)
PR1 11 (14)
PR2/CR2 61 (80)
Refractory 2 (3)
DLBCL indicates diffuse large B cell lymphoma; NHL, non-hodgkin lym-
phoma; ASCT, autologous stem cell transplantation; CR, complete re-
mission; PR, partial remission.
*For status at ASCT, data for 2 (2%) patients are missing.
Table 3. Transplantation Outcomes and Toxicity
Event
Days to neutrophil engraftment, median (range) 10 (7, 17)
Days to platelet engraftment, median (range) 17 (6, 576)
Hospital stay, days, median (range) 20 (11, 140)
Infection, n (%)
Bacterial 9 (12)
Fungal 0 (0)
Viral 2 (3)
Engraftment syndrome, n (%) 4 (5)
VOD, n (%) 3 (4)
Cardiac toxicity, n (%) 6 (8)
Hemorrhagic cystitis, n (%) 0 (0)
Pulmonary fibrosis, n (%) 2 (3)
Central nervous system toxicity, n (%) 0 (0)
100-day TRM, n (%) 1 (1)
MDS or AML, n (%) 0 (0)
VOD indicates veno-occlusive disease; TRM, treatment-related mortal-
ity; MDS, myelodysplastic syndrome; AML, acute myelogenous leukemia.
Neutrophil engraftment was defined by ANC > 500 on 2 consecutive
days.
Platelet engraftment was defined by platelets > 50,000/UL on 2 consec-
utive days unsupported by transfusions.
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median patient age was 57 years (range, 24-78 years).
The most common diagnosis was diffuse large B cell
lymphoma (DLBCL), followed by follicular NHL.
All but 3 patients underwent ASCT using PBSC alone.
A total of 24 patients received oral busulfan, whereas
54 received the i.v. formulation. The median number
of previous chemotherapy regimens received before
ASCT was 2 (range, 1-4), as shown in Table 2. Both
of the patients who underwent ASCT while in first
CR (CR1) had a diagnosis of mantle cell lymphoma.
The median duration of inpatient hospital stay was
20 days (range, 11-140 days), with a median time to en-
graftment of 10 days for neutrophils (range, 7-17 days)
and 17 days for platelets (range, 6-576 days). No pa-
tients in this series experienced autograft failure.Toxicities
Toxicity and outcome data are summarized in
Table 3. Nine patients developed a documented bacte-
rial infection during the first 100 days post-ASCT. Six
of these infections were Clostridium difficile colitis; all
cases were treated with oral metronidazole, and all
resolved. The other 3 bacterial infections were docu-
mented episodes of bacteremia. One patient had blood
cultures positive for Micrococcus sp and coagulase-Table 2. Number of Chemotherapy Regimens (n5 76)
Number of Chemotherapy Regimens n (%)
1 4 (5%)
2 58 (74%)
3 13 (17%)
4 3 (4%)negative Staphylococcus, although he did not develop
a fever during his entire hospitalization. Another
patient had cultures positive for Stenotrophomonas mal-
tophilia about 1 month post-ASCT. He had his central
venous catheter removed and improved on a course of
antibiotics, and subsequently was discharged in good
condition. A third patient developed clinical findings
of acalculous cholecystitis, with blood cultures positive
for 2 species of Enterococcus before engraftment. He
was treated with antibiotics, underwent biliary stent
placement, had his indwelling venous catheter
removed, and recovered uneventfully. Two viral infec-
tions were noted within 100 days post-ASCT.The first
was an infection with parainfluenza-3, which led to
hospitalization at about 6 weeks post-ASCT. With
supportive care, the patient’s symptoms improved,
and he was discharged in good condition. The second
viral infection was in an human immunodeficiency
virus (HIV)-positive patient who developed cytomeg-
alovirus (CMV) reactivation detected by blood CMV
antigenemia assay 2 months post-ASCT. He was hos-
pitalized and treated with i.v. ganciclovir; further
investigation revealed recurrence of lymphoma. The
patient eventually died during this hospitalization,
with the cause of death attributed to recurrent NHL.
No fungal infections were documented in any patient.
There were no cases of neurologic toxicity or hem-
orrhagic cystitis. Four patients had symptoms consis-
tent with engraftment syndrome, all of which resolved
before discharge from the hospital with a short course
of systemic corticosteroid therapy. Three patients
developed findings consistent with hepatic VOD;
none of the cases was fatal. One patient had trans-
formed follicular lymphoma (FL) and presented about
1 month post-ASCT with elevated serum bilirubin,
a 10-pound weight gain, and evidence of new ascites.
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cyclophosphamide-doxorubicin-vincristine-predniso-
lone (CHOP) for initial therapy for follicular NHL.
Four months later, he was diagnosed with DLBCL
and underwent 1 cycle of E-methylprednisolone-cytar-
abine-cisplatin followed by 3 cycles of E-vincristine-
doxorubicin-Cy-prednisolone before achieving PR.
Two months later, he underwent ASCT using oral bu-
sulfan. He was admitted for the aforementioned symp-
toms and treated supportively with i.v. diuretics,
ursodiol, and albumin transfusions. His bilirubin
peaked at 4.1 mg/dL (direct, 2.4 mg/dL), and he was
discharged on oral diuretics with continued improve-
ment and resolution of VOD. The second patient had
DLBCL and had been treated with CHOP followed
by mediastinal radiation therapy that led to remission;
however, she relapsed 2 months after the completion
of therapy. She then received ifosamide-carboplatin-
etoposide (ICE) and achieved PR, then underwent
ASCT with oral Bu. At about 2 weeks post- ASCT,
she had a total bilirubin of 3.0 mg/dL (direct, 2.2 mg/
dL). She reported mild tenderness in the right upper
quadrant and a 3-poundweight gain.No ascites was de-
tected on imaging, and her serum creatinine remained
stable. She did not require diuretic therapy, and her bil-
irubin trended down over the next few days after reach-
ing a peak of 3.4 mg/dL. The third patient had
a diagnosis of follicular large cell lymphoma and re-
ceived 6 courses of CHOP, with disease progression
noted at 2-month follow-up. He received salvage ther-
apy with etoposide-ifosfamide-methotrexate and local
radiation therapy to the buccal area of the oral cavity.
Five years later, he experienced a relapse in the inguinal
nodes and was treated with dexamethasone-cytarabine-
cisplatin and achieved PR, then underwent ASCT with
oral Bu. By day 9 post-ASCT, he had gained 7 pounds
and had a serum bilirubin of 1.9 mg/dL. His INR rose
to 2, and abdominal ultrasound revealed ascites.He was
treated supportively, and his symptoms improved.
There were no cases of acute cardiomyopathy, but
5 patients experienced transient episodes of atrial
fibrillation and 1 patient developed pericarditis. No
cases of secondary myeodysplastic syndrome (MDS)
or acute myelogenous leukemia (AML) were reported.
Pulmonary fibrosis developed in 2 patients after trans-
plantation, which was diagnosed by pulmonary func-
tion testing and radiographic studies. The first
patient developed shortness of breath 4 months post-
ASCT, at which point his DLCO had dropped from
80% to 29% of predicted (corrected for hemoglobin
level). His previous treatment was notable for both
bleomycin and radiation therapy to the chest, and it
was thought that all 3 factors likely contributed to
the development of his interstitial lung disease. The
second patient noted the onset of symptoms about 14
months post-ASCT. Pulmonary function tests at that
time revealed a DLCO of 53% of predicted, comparedwith 74% at the time of transplantation. He improved
on corticosteroid therapy, but a presumed viral infec-
tion led to clinical worsening about 2 years post-
ASCT, necessitating hospitalization and mechanical
ventilatory support and ultimately leading to death.
A lung biopsy specimen demonstrated diffuse alveolar
damage in the proliferative phase, thought to be con-
sistent with late busulfan-associated lung injury.
Mortality
The 100-day treatment-related mortality (TRM)
in this series was 1.3%, with 1 patient dying of clinical
sepsis and multifocal pneumonia about 50 days after
transplantation at another hospital without any clearly
identified infectious organism. Five other deaths oc-
curring within 100 days post-ASCT included 4 related
to disease recurrence and 1 related to the development
of a newly diagnosed malignancy. Two patients who
experienced an early fatal recurrence had HIV-associ-
ated NHL. The newly diagnosed malignancy was
a rapidly progressive metastatic melanoma noted 51
days post-ASCT, leading to death at 55 days post-
ASCT. Both of the 2 HIV-negative patients with early
relapse had a diagnosis of DLBCL. Both patients un-
derwent initial therapy with 6 cycles of CHOP, leading
to CR. The first patient experienced a recurrence 17
months later and underwent salvage ICE chemother-
apy for 3 cycles, which led to PR. He underwent
ASCT using oral Bu. At about 2 months post-ASCT,
he presented with abdominal pain, jaundice, and acute
renal failure, and he ultimately died of multiorgan fail-
ure. His symptoms initially were considered related to
VOD; however, autopsy revealed diffuse involvement
of the hepatic tissue with lymphoma. The second pa-
tient experienced disease recurrence about 9 months
after initial remission. She received 2 cycles of ICE
and exhibited a PR. She then underwent ASCT with
i.v. busulfan. Routine restaging scans on around day
100 post-ASCT suggested disease recurrence in the
liver, spleen, and abdominal lymph nodes. She was
treated with high-dose cytarabine plus rituximab,
which was complicated by admission for fever and neu-
tropenia. At that time, she had an increasing bilirubin
level, consistent with progression of hepatic disease.
She died soon thereafter.
Outcomes
Median duration of follow-up for survivors was 5.0
years (range, 6 months to 12 years). Figures 1 and 2 il-
lustrate Kaplan-Meier curves for PFS and OS, respec-
tively, in all patients. As shown in Table 4, PFS at 3
years was 48% (95% confidence interval [CI]5 37%
to 59%) and OS at 3 years was 65% (95% CI5 53%
to 74%). At 5 years, PFS was 36% (95% CI5 24% to
48%) and OS was 59% (95% CI5 46% to 69%). As
shown in Table 5, for the 37 patients with a diagnosis
Table 4. PFS and OS for All Patients (n5 78)
95% CI
%
Lower Confidence
Limit, %
Upper Confidence
Limit, %
OS
3-year 64.8 52.9 74.4
5-year 58.7 46.1 69.4
PFS
3-year 48.2 36.6 58.8
5-year 35.6 23.9 47.5
PFS indicates progression-free survival; OS, overall survival.
Median follow-up for patients is 5.0 years (range, 6 months to 12 years).
Figure 1. OS and PFS for all patients (n5 78).
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58%), 3-year OS was 59% (95% CI5 42% to 73%),
5-year PFS was 30% (95% CI5 14% to 47%), and
5-year OS was 51% (95% CI5 32% to 66%).
Cox regression analysis was performed to identify
factors associated with OS and PFS (Table 6). Factors
analyzed included age, patient sex, histology of NHL,
number of previous chemotherapy regimens, disease
status at ASCT, and year of transplantation (before
vs after December 2000, when the transition was
made from oral to i.v. Bu). Results of the Cox model
analysis demonstrated that disease type and number
of previous chemotherapy regimens were significantly
associated with OS and PFS. In particular, patients
with DLBCL did worse relative to other histologies,
with a hazard ratio (HR) of 5.87 (P5 .01) for OS and
2.31 (P5 .04) for PFS.Figure 2. OS and PFS for patients with DLBCL (n5 37).DISCUSSION
Our series, which reports the results of 78 consec-
utive patients, is the largest published series using
BuCy in patients with NHL. Long-term disease-free
survival (DFS) rates ranging from 28% to 60% have
been reported after ASCT for relapsed and refractory
aggressive NHL using various combination high-dose
chemotherapy regimens [2,13-17]. No regimen has
ever proven superior to another in a prospective ran-
domized clinical trial. Our results, with a 3-year PFS
of 48%, 3-year OS of 65%, 5-year PFS of 36%, and
5-year OS of 59%, are comparable to those of
previously reported series using other regimens, as
summarized in Table 7 [2,8,14-24].
A few smaller studies in different patient popula-
tions using Bu/Cy have been reported previously.
One series of 22 patients with low-grade NHL
reported 2 transplantation-related deaths, a PFS of
36%, and an OS of 58% at 3.6 years of follow-up
[23]. Another series comprising 21 patients with
NHL reported 1 transplantation-related death and
an OS of 51% over the 34-month monitoring period
[19]. A third study of 16 patients with NHL reported
no transplantation-related deaths, an OS of 50%, and
an event-free survival of 33% at 2 years [21]. All of
these studies used oral busulfan, which has been com-
monly considered associated with increased toxicity
compared with i.v. Bu because of variations inTable 5. OS and PFS for Patients with DLBCL (n5 37)
95% CI
%
Lower Confidence
Limit, %
Upper Confidence
Limit, %
OS
3-year 59.2 41.7 73.1
5-year 50.7 32.3 66.4
PFS
3-year 43.2 27.2 58.3
5-year 29.7 14.4 46.7
PFS indicates progression-free survival; OS, overall survival; DLBCL, dif-
fuse large B cell lymphoma.
Table 6. Cox Regression Analysis on all Patients (n5 78)
OS (n5 78)* PFS (n5 78)*
Variable HR 95% CI P HR 95% CI P
Age 0.99 0.96-1.02 .52 1.00 0.98-1.03 .95
Male sex 0.81 0.37-1.77 .59 0.82 0.44-1.53 .53
DLBCL 5.87 1.64-20.98 .01 2.31 1.04-5.13 .04
Mixed 5.15 0.78-33.83 .09 4.91 1.44-16.77 .01
Other 4.35 1.02-18.54 .05 1.24 0.42-3.65 .70
Previous chemotherapy regimens 2.05 1.14-3.70 .02 2.13 1.24-3.67 .01
CR/Cru 0.57 0.05-6.43 .65 1.89 0.20-18.06 .58
PR 1.02 0.11-9.40 .99 1.66 0.19-14.58 .65
Year of ASCT (after December 2000) 0.48 0.21-1.10 .08 0.63 0.33-1.20 .16
DLBCL indicates diffuse large B cell lymphoma; CR, complete remission; PR, partial remission; ASCT, autologous stem cell transplantation.
*Wald test P value for the coefficient.
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cantly when comparing ASCT performed with oral
versus i.v. Bu, although there was a trend toward im-
proved survival with i.v. use (HR5 0.48; 95%
CI5 0.21-1.10; P5 .08). A recent report by Aggarwal
et al. [18] noted a significant benefit in PFS and OS
with the use of i.v. Bu in patients undergoing ASCT
using BuCyE, with significant reductions in nonre-
lapse mortality mainly from hepatic VOD and pulmo-
nary complications.
One series that used primarily i.v. busulfan reported
the outcomes of patients with HIV-associated lym-
phoma undergoing ASCT, a few of whom are included
in our series [11]. In the 20 patients who proceeded to
ASCT, 1 transplantation-related death occurred, re-
sulting from VOD. OS was poorer, as expected, with
a median OS of only 23 weeks [11]. This is in contrast
to the recent study byDiez-Martin et al. [25], which re-
ported comparable survival in patients with HIV-posi-
tive and HIV-negative NHL after ASCT. With only 6
HIV-positive patients in our series, it is difficult to draw
meaningful conclusions for this population with this
specific conditioning regimen.Table 7. Comparison with Other Autologous Conditioning Regime
Authors n Regimen Foll
Fernandez [26] 44 i.v. Bu/Cy
Hanel et al. [14] 43 Oral Bu/Cy/E
DeMagalhaes-Silverman et al. [21] 20 PO Bu/Cy
Philip et al. [2] 54 Cy/TBI
Kim et al. [8] 64 i.v. Bu/Cy/E
Copelan et al. [20] 382 Oral Bu/Cy/E
Zaucha et al. [24] 58 Oral Bu/Me/lTT
Zaucha et al. [24] 49 BEAM
Aggarwal et al. [18] 18 Oral Bu/Cy/E
Aggarwal et al. [18] 31 i.v. Bu/Cy/E
Weaver et al. [23] 22 Oral Bu/Cy
Stiff et al. [16] 94 CBV CyVP TBI
Ballester et al. [19] 21 Oral Bu/Cy
Schiffman et al. [22] 40 Bu/Me/lTT
Stein et al. [15] 99 CBV CyVP TBI
Wadhwa et al. [17] 101 BEP
Current study 78 Bu/Cy
NR indicates not reported; Bu, busulfan; Cy, cyclophosphamide; Mel, melphalIn our series, 100-day TRM was quite low at 1%,
and transplantation-related toxicities also were mini-
mal even without routine measurements of pharmaco-
kinetic data onBudosing. Bu lung toxicitywas themost
significant complication; it occurred in only 2 patients,
at 4 months and 14 months post-ASCT. The first pa-
tient is still alive, although with persistent pulmonary
disability, whereas the second patient died from com-
plications related to lung disease 2 years post-ASCT.
Cardiac toxicity occurred in 8% of patients; however,
most of these events were transient episodes of atrial fi-
brillation that were not clinically significant. There
were no episodes of acute cardiomyopathy. Only 3 pa-
tients developed clinically significant hepatic VOD; all
of these had been treated during the oral Bu era. All 3
patients survived with supportive care alone. Finally,
there have been no cases of secondary MDS/AML in
this series thus far. As shown in Table 7, TRM and
VOD rates are quite low compared with other pub-
lished series, indicating that this regimen is well toler-
ated in this population. Compared with older regimens
using oral Bu, it is likely that the improved accuracy of
dosing of i.v. Bu has led to less toxicity. Compared withns and Series
ow-Up, Years OS, % DFS, % TRM, % VOD, %
3.5 45 44 9.1 4.6
3 43 31 3.8 5.8
2 50 33 5 15
5 53 46 5.6 NR
3 69 NR 3 6.3
3 NR 47 2.6 2.9
4 63 47 10 NR
4 52 35 NR NR
5 28 17 28 NR
5 58 50 3 NR
3.6 58 36 9 NR
3 44 46 10.6 NR
3.8 51 NR 4.7
2 60 41 17 23
5 34 26 9 NR
3.5 59 51 4 NR
3 65 48 1 3.8
5 59 36 1 3.8
an; E, etoposide; TBI, total body irradiation.
Biol Blood Marrow Transplant 15:1447-1454, 2009 1453BuCy as a Preparative Regimen for ASCT in NHLBu/Cy/E, the omission of etoposide likely has pre-
vented significant mucosal toxicity, as well as higher
rates of VOD and secondary MDS/AML.
Given the observed comparable efficacy and low
toxicity, Bu/Cy appears to be a reasonable preparative
regimen before ASCT in patients with NHL. Cox
regression analysis performed on multiple clinical fac-
tors did not suggest a specific population that would
specifically benefit from Bu/Cy. International Prog-
nostic Index scores either at diagnosis or relapse could
not be analyzed given the incomplete data available.
Regardless, the low toxicity seen with this regimen
may suggest that it is an ideal regimen for older
patients or those with some comorbidities who may
not otherwise tolerate more aggressive regimens.
Recently, our group reported the experience of using
Bu/Cy specifically in elderly patients with NHL
(some of whom are included in the present series),
with very little toxicity and encouraging outcomes
[12]. As long as efficacy is maintained, limiting the
number of agents used decreases the agent-specific
toxicities and overall treatment-related morbidity
and TRM.
In summary, Bu/Cy is a well-tolerated regimen
associated with low rates of acute and chronic trans-
plantation-related toxicities. Long-term rates of OS
and PFS appear to be comparable to those of other
published preparative regimens with ASCT. Given
that the most common histology in patients with
NHL undergoing ASCT is DLBCL, the lack of toxic-
ity and comparable outcomes in this subgroup of
patients is especially notable. We hope that describing
the clinical outcomes of this preparative regimen for
ASCT can facilitate more comparisons to explore
whether there are significant differences in efficacy
or toxicity between regimens.ACKNOWLEDGMENTS
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